TY - JOUR
T1 - Baboons undergoing orthotopic concordant cardiac xenotransplantation surviving more than 300 days
T2 - Effect of immunosuppressive regimen
AU - Asano, Miki
AU - Gundry, Steven R.
AU - Izutani, Hironori
AU - Cannarella, Sandra Nehlsen
AU - Fagoaga, Omar
AU - Bailey, Leonard L.
AU - Michler, Robert E.
PY - 2003/1/1
Y1 - 2003/1/1
N2 - Objective: We reviewed long-term survival among hosts in 3 consecutive series of a rhesus monkey-baboon orthotopic cardiac xenotransplantation model with reference to host immune response, including the effectiveness in preventing rejection and limiting toxicity concerning infection, to evaluate specific immunosuppressive regimens for long-term outcomes. Methods: Six juvenile baboons surviving more than 300 days after transplantation were reviewed. Regimen A consisted of splenectomy, FK506, methotrexate, and antilymphocyte globulin. Regimen B consisted of pretransplantation and chronic maintenance with cyclosporine A (INN: ciclosporin), methotrexate, and antithymocyte globulin. Regimen C was the same as regimen B plus pretransplantation total lymphoid irradiation and intraoperative donor bone marrow cell infusion. Rejections were detected by means of echocardiography. Results: Long-term survivors in 3 groups were followed for a range of 332 to 515 days (mean, 436 days). Rejection frequency in regimens A, B, and C was 0.35, 0.58, and 0.18 per month, and rescue therapy days were 23 (4.8%), 123 (9.5%), and 20 (2.4%), respectively (P < .0001). Infection frequency was 0.58, 0.56, and 0.19 per month, and therapy days were 192 (38.2%), 164 (12.6%), and 7 (0.9%), respectively (P < .0001). Concerning the host immune response, interleukiri 2-activated T cells of all groups during rejection-free periods showed lower numbers compared with those of control animals (P < .0005), and regimen C was the lowest among 3 groups (P < .01). The production of xenoantibody was sufficiently attenuated in all groups. Conclusion: Regimen C leads to long-term survival with fewer rejection and infection episodes by means of suppression of the interleukin 2 pathway and xenoantibody production.
AB - Objective: We reviewed long-term survival among hosts in 3 consecutive series of a rhesus monkey-baboon orthotopic cardiac xenotransplantation model with reference to host immune response, including the effectiveness in preventing rejection and limiting toxicity concerning infection, to evaluate specific immunosuppressive regimens for long-term outcomes. Methods: Six juvenile baboons surviving more than 300 days after transplantation were reviewed. Regimen A consisted of splenectomy, FK506, methotrexate, and antilymphocyte globulin. Regimen B consisted of pretransplantation and chronic maintenance with cyclosporine A (INN: ciclosporin), methotrexate, and antithymocyte globulin. Regimen C was the same as regimen B plus pretransplantation total lymphoid irradiation and intraoperative donor bone marrow cell infusion. Rejections were detected by means of echocardiography. Results: Long-term survivors in 3 groups were followed for a range of 332 to 515 days (mean, 436 days). Rejection frequency in regimens A, B, and C was 0.35, 0.58, and 0.18 per month, and rescue therapy days were 23 (4.8%), 123 (9.5%), and 20 (2.4%), respectively (P < .0001). Infection frequency was 0.58, 0.56, and 0.19 per month, and therapy days were 192 (38.2%), 164 (12.6%), and 7 (0.9%), respectively (P < .0001). Concerning the host immune response, interleukiri 2-activated T cells of all groups during rejection-free periods showed lower numbers compared with those of control animals (P < .0005), and regimen C was the lowest among 3 groups (P < .01). The production of xenoantibody was sufficiently attenuated in all groups. Conclusion: Regimen C leads to long-term survival with fewer rejection and infection episodes by means of suppression of the interleukin 2 pathway and xenoantibody production.
UR - http://www.scopus.com/inward/record.url?scp=0037252071&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037252071&partnerID=8YFLogxK
U2 - 10.1067/mtc.2003.89
DO - 10.1067/mtc.2003.89
M3 - Article
C2 - 12538986
AN - SCOPUS:0037252071
SN - 0022-5223
VL - 125
SP - 60
EP - 70
JO - Journal of Thoracic and Cardiovascular Surgery
JF - Journal of Thoracic and Cardiovascular Surgery
IS - 1
ER -